trading pattern, page-112

Hi Pman,

"I have a sneaking suspicion they got burnt/frustrated with the posts being moved for the Transdermal patch that was 10 times better, yet nothing since marketing review"

This is the BIG FISH that won't be getting away imo - especially after +5 years ;)

A quick trip down memory lane might help restore your confidence..., Pman.
___

FMCG #1

29 October 2008
"In December 2007, OBJ executed a research collaboration agreement with the same FMCG company to conduct an initial feasibility to evaluate the use of both the DP and ETP platforms for up to 2 compounds for over-the-counter (OTC) healthcare applications. The initial feasibility was successfully completed in March 2008.

OBJ Director Glyn Denison said that this second feasibility agreement was an important milestone for OBJ, as successful completion of the project may lead to significant commercial outcomes for the Company."
___

01 October 2009
"The report by Azopharma Contract Services Inc, a GLP/GMP accredited contract research organisation in Miami Florida, sets out the results of an eight-month patch development and evaluation program. The study tested the delivery performance of OBJ’s Dermaportation and ETP technologies in a fully formulated patch format, when compared to an existing Over the Counter (OTC) drug product with significant international sales.

Under the terms of the Agreement, OBJ is restricted from disclosing any information relating to the drug tested, the comparative product or the market.

The Azopharma Report, which remains the property of the FMCG company, stated in the Executive Summary that:

“The developed patch system effectively fluxes approximately a 10-fold over the existing product comparatively”

“The development work to this point justifies proof of concept of the formulation and technology to proceed further into the pharmaceutical development of a drug product.”
___

08 February 2010
"OBJ Limited is pleased to advise that it has received a Statement of Intent from a global FMCG (Fast Moving Consumer Goods) company in regards to an ongoing product development program utilising OBJ’s ETP and DP technologies.

This FMCG company has permitted the release of the following statement:

“OBJ is continuing to work with a major healthcare company to develop a product to enhance the delivery of one of their key therapeutic agents”

* Imo, this very vague and limited statement permitted for release by our FMCG#1 partner gives us some indication of the commercial significance this project is for them.
___

30 November 2010
"There are a number of stages that any licensing arrangement must pass through that would enable a targeted partnering company to adopt the OBJ technology as a preferred drug delivery alternative. This includes undergoing its own internal testing program, its own product marketing development program, a technical and manufacturing development process and final manufacture and distribution. This process can often be measured in years and the timelines are very much controlled by the partnering company."
___

11 February 2011
"The company previously announced it had entered into a second agreement for advanced feasibility development of magnetically enhanced patch implementations of an important OTC drug compound with worldwide sales. The advanced feasibility program investigated the level of performance enhancement provided by both Dermaportation and ETP in a fully developed patch formulation against an existing and established gel product with international sales.

The patch formulation, patch proto-typing and in vitro testing components of this program were conducted in the USA. Following the completion of the formulation and stability studies, the Company provided a range of Dermaportation fields and ETP materials for direct comparative testing against the established gel product. Over the study period the Dermaportation and ETP materials were optimised to the Azopharma formulation and data on the rates of penetration through human epidermis were generated. The level of enhanced delivery over and above that of the established gel product met the Company's expectations for both Dermaportation and ETP technologies."
___

5 April 2011
"The Company’s collaboration with a second major international FMCG, initially announced in 2009, has progressed through a number of stages of technical evaluation and has more recently been subjected to consumer studies. As a consequence of the response to date, this development program has now moved to being reviewed by FMCG’s international marketing department.

In addition, interest from another product group within the same FMCG company has created further potential product development opportunities for the Company. The use of drug delivery technology in this category, if adopted, will be a further demonstration of the versatility of the Company’s technologies.
___

30 September 2011
"During the reporting period, the Company accepted an invitation to present at the prestigious BioPartnering Conference in London. At the same time, the Company announced that consumer studies by a major FMCG company had commenced into a key OTC pharmaceutical application with encouraging results. Discussions in this area are ongoing with more than one international partner now interested in progressing this application in collaboration with the Company.

On topical drug delivery in general, (both OTC and Rx), we are now engaging the interests of more than one large Healthcare company."
___

25 November 2011 - AGM: Corporate Presentation
A Year of Progress

FMCG 1 (USA) - Strategic Alliance Negotiations
FMCG 2 (UK) - Development Discussions
GSK Oral Health - Human Efficacy Studies
FMCG 3 (Global) - JDA Negotiations
OBJ Sponsored Products - Consumer Concept Testing
Major US Pharma - Multi-product discussions
___

25 November 2011 - AGM: Q&A with Glyn

Question from bassman: What do you think the outlook is for obj over the next 12 months?

Glyn: "I dont like to speculate but we hope to have at least one licencing agreement in place."
___

Question from coppertop01: How many companies is obj in negotiations with?

Glyn: "Five"
___

Question from Pman: Has any company walked away from negotiations or turned down the company recently (last 12 months)?

Glyn: "None, no programs have been abandoned."
___

Question from Ripplestick: Is FMCG#1 still interested and progressing with OBJ in respect of its OTC drug product?

Question from Pman: Regarding FMCG#1 - as announced in the April 2011 shareholder update, "another product group within the same FMCG company has created further potential product development opportunities for the Company" when do you consider drawing a line through the FMCG#1 and taking it to the next party?

Glyn: "We are working aggressively with both companies in different categories - no programs have been abandonded"